Skip to main content
SpringerPlus
Figure 5 | SpringerPlus

Figure 5

From: Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling

Figure 5

Results of a virtual clinical trial for tamoxifen-endoxifen fixed dose combination. Box-whisker-plots indicate the percentiles 5, 25, 50, 75, and 95 of the population simulation results. Shaded grey areas represent median and the percentiles 5 and 95 of simulated reference steady-state CYP2D6 EM levels (acc. to Figure 3) as target concentration ranges for all fixed-dose combinations. A standard dosage of 20 mg tamoxifen was used for all simulations. Abbreviations used in diagram: tamoxifen (TAM), N-desmethyltamoxifen (NDM), 4-hydroxytamoxifen (4OH), endoxifen (END), cytochrome P450 2D6 (CYP2D6), intermediate metabolizer (IM), poor metabolizer (PM), fixed-dose combination (FDC).

Back to article page